2. UroToday Home
  3. Conference Highlights
  4. ASCO 2017

ASCO 2017 Bladder Cancer

ASCO 2017: Astellas and Seattle Genetics Announce Updated Enfortumab Vedotin Phase 1 Data in Metastatic Urothelial Cancer

Chicago, IL (UroToday.com) Updated phase 1 data for enfortumab vedotin (ASG-22ME) studied as monotherapy treatment for metastatic urothelial cancer (mUC) was highlighted in an oral presentation at the American Society of Clinical Oncology (ASCO) 52nd Annual Meeting in Chicago.

ASCO 2017: The clinical role of purified protein derivative skin test reaction in patients with non-muscle invasive bladder cancer treated with bacillus-Calmette Guerin

Chicago, IL (UroToday.com) Non-muscle invasive bladder cancer (NMIBC) still represents 70% of the patients who present with bladder cancer (BC). High-grade NMIBC represents a particularly troublesome cohort for whom clinical progression to MIBC remains a high risk, but for whom there are not many treatment options.

ASCO 2017: Cabazitaxel in patients with locally advanced or metastatic transitional cell carcinoma who developed disease progression within 12 months of platinum based chemotherapy: Results of a phase II trial—CAB-B1.

Chicago, IL (UroToday.com) In the past 1 year, five different immune checkpoint inhibitors have been approved by the FDA approved for the treatment of metastatic or advanced urothelial carcinoma (UC): atezolizumab, durvalumab, nivolumab, pembrolizumab and most recently avelumab.

ASCO 2017: Effectiveness of the Moreau strain of Bacillus Calmette-Guerin (BCG) for nonmuscle invasive bladder cancer

Chicago, IL (UroToday.com) Non-muscle invasive bladder cancer (NMIBC) still represents 70% of the patients who present with bladder cancer (BC). High-grade NMIBC represents a particularly troublesome cohort for whom clinical progression to MIBC remains a high risk, but for whom there are not many treatment options.

ASCO 2017: Survival outcomes in elderly patients with muscle invasive bladder cancer: An analysis of the National Cancer Database

Chicago, IL (UroToday.com) Muscle-invasive bladder cancer (MIBC) is a disease process for which we have not made much inroads in the past few decades; despite the introduction of neoadjuvant chemotherapy (NAC), the survival for patients with MIBC has remained relatively unchanged.

ASCO 2017: Comprehensive molecular characterization and analysis of muscle-invasive urothelial carcinomas

Chicago, IL (UroToday.com) Dr. Lerner presented a continuation of a study published in 2014 on 131 tumors that had integrated molecular analysis.1  This original publication analyzed 131 tumors of advanced bladder urothelial carcinoma showing 32 significantly mutated genes, 9 not previously reported. This current presentation focused on the follow-up analysis of the entire cohort, composed of 412 tumors from the TCGA project in chemotherapy-naïve, muscle-invasive urothelial bladder cancer. 

ASCO 2017: Epacadostat plus pembrolizumab in patients with advanced urothelial carcinoma: Preliminary phase I/II results of ECHO-202/KEYNOTE-037

Chicago, IL (UroToday.com) Pembrolizumab (Pembro), a PD-1 inhibitor, is active and well tolerated in platinum-treated, advanced urothelial carcinoma (UC) patients. Epacadostat (Epac) potently and selectively inhibits indoleamine 2,3-dioxygenase 1 (IDO1), a tryptophan-catabolizing enzyme that suppresses T-cell–mediated immune surveillance. IDO1 overexpression is associated with tumor progression and shortened patient survival.
Page 1 of 4
E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe